VDR agonist 4

VDR agonist 4 is an orally active potent VDR agonist. VDR agonist 4 exerts VDR-dependent antifibrotic activity by regulating multiple fibrosis-related genes to suppress α-SMA and collagen I production, thereby inhibiting hepatic stellate cell (HSC) activation. VDR agonist 4 improves CCl4 (HY-RS16594) -induced hepatic fibrosis in mice. VDR agonist 4 can be used for liver fibrosis research[1].

Product Specifications

UNSPSC

12352005

Target

Collagen; JAK; MMP; TGF-beta/Smad; VD/VDR

Related Pathways

Cytoskeleton; Epigenetics; JAK/STAT Signaling; Metabolic Enzyme/Protease; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt; TGF-beta/Smad; Vitamin D Related/Nuclear Receptor

Field of Research

Endocrinology; Metabolic Disease; Inflammation/Immunology

Smiles

CCN(C(CCCCCOC1=CC2=CC=C(C=C2C=C1)OCC3=C[C@H]([C@H]([C@@H](C3)O)O)O)=O)CC

Molecular Formula

C27H37NO6

Molecular Weight

471.59

References & Citations

[1]Gao Y, et al. Design, Synthesis, and Evaluation of Antifibrotic Activity of Nonsteroidal VDR Agonists Featuring 1,6-Naphthol as a CD-Ring Surrogate. J Med Chem. 2025 Oct 9;68 (19) :20561-20585.